Allianz Achieves Record Operating Profit of 17.4 Billion Euros – Excellent Start to New Strategic Cycle February 26, 2026 12M 2025 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260225107874/en/ Excellent momentum and record operating profit Total business volume rises 8.11 percent and reaches 186.9 billion euros with contributions from all segments Operating profit increases 8.4 percent to 17.4 billion euros, our highest operating profit ever Shareholders’ core net income advances 10.9 [...]
The £1bn company with no staff? Why AI is a gift to Britain’s small businesses February 26, 2026 With branding built on Canva, market research synthesised in seconds or client decks as slick as McKinsey’s, could we say now that for the first time, a five-person firm can present like a 50-person one, and potentially undercut and outmanoeuvre larger rivals? Asks Eliza Filby In Silicon Valley, investors are salivating at the thought of [...]
There’s no evidence that social media is killing teens February 26, 2026 Kemi Badenoch would have you believe we are in the midst of a terrifying epidemic of teen suicide to which the answer is a social media ban. But the data tells a different story, says Tom Harwood Politics needs more weirdos and misfits. When former Downing Street chief advisor Dominic Cummings put out the call [...]
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing February 25, 2026 VH184, the first, third‑generation integrase inhibitor in development shows potential for up to twice-yearly dosing intervals Additional in-vitro data on VH184 demonstrate improved potency and an enhanced resistance profile versus bictegravir VH499 demonstrates good tolerability, supporting twice-yearly dosing intervals
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen February 25, 2026 94% of adults on stable therapy maintained viral suppression with intravenous lotivibart dosed every four months in combination with long-acting cabotegravir These phase IIb results reinforce lotivibart’s ultra long-acting potential, with the trial progressing to evaluate a twice-yearly intravenous dosing interval
Gucci sparks backlash with AI-generated ads ahead of fashion week February 25, 2026 Gucci has come under fire after using AI to create images promoting its upcoming show at Milan fashion week, raising concerns that the luxury house is cutting corners ahead of a runway debut. The Italian brand posted a series of glossy visuals on social media this week, some labelled ‘created with AI’, to tease creative [...]
Extend Launches CIP: a Cultural Intelligence Platform Empowering Marketers to Plan, Manage, and Monitor Campaigns Directly Through Its Marketing Platform February 25, 2026 Extend CIP unifies years of product and agency experience into a single platform for marketers across the Arab world, launching with the region's largest influencer ad library and end-to-end campaign tools
Airspan Networks Expands 5G In-Motion Platform into Defense MANET, High-Altitude Platforms, and Drones February 25, 2026 Introducing a resilient advanced communications bridge between terrestrial and aerial networks
NYU Abu Dhabi and RTW Investments Announce Strategic Collaboration to Advance Healthcare and Life Sciences Innovation February 25, 2026 Partnership will deliver executive programs and convene global investors, policymakers, and experts to strengthen the region’s healthcare ecosystem
Alkermes plc Announces CEO Succession Plan February 25, 2026 — Richard Pops to Retire from Role of Chief Executive Officer Following Distinguished 35-year Career with Alkermes — — Board of Directors Appointed Blair Jackson, Alkermes’ Current Executive Vice President, Chief Operating Officer, as CEO Effective as of August 1, 2026 — — Richard Pops to Continue to Serve as Chairman of the Alkermes Board of Directors —